Skip to main content

Featured

CUSMA Review 2026: What Happens on July 1 — and What It Means for Your Wallet

The trade deal that governs nearly $1.3 trillion in Canada-U.S. commerce is up for review in less than a week. Here's what's at stake for Canadian families — and how to protect your budget whatever happens next. By MoneySavings.ca Staff  |   June 25, 2026 Canada Day is almost here — and this year, July 1 carries a lot more weight than fireworks and barbecues. On that same date, Canada, the United States, and Mexico are required to sit down for the first mandatory review of the Canada–United States–Mexico Agreement , known in Canada as CUSMA (and in the U.S. as the USMCA). The outcome of these talks will help shape the price of your groceries, your next car payment, Canadian jobs, and the overall cost of living for years to come. If you've heard the buzz but aren't sure what it all means for your household budget, you're in the right place. Here's your plain-language breakdown. What Is CUSMA — and Why Should You Care? CUSMA replaced the old NAFTA deal in 2020 an...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment